Delays in surgery to treat early-stage breast cancer and receiving neoadjuvant endocrine therapy did not decrease survival odds among female patients, authors report in the Journal of the American College of Surgeons.
Overall delays in surgical procedures to treat early-stage breast cancer, particularly estrogen-sensitive early-stage disease, as well as receiving neoadjuvant endocrine therapy (NET) because of such a delay, did not decrease odds of 5-year survival or increase odds of pathologic upstaging among a cohort of female patients, authors report in the Journal of the American College of Surgeons. [Read more…]